Affimed Analyst Ratings
Affimed Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/07/2023 | 1270.67% | Cantor Fitzgerald | → $7 | Reiterates | Overweight → Overweight |
| 08/11/2023 | 1074.86% | Truist Securities | $8 → $6 | Maintains | Buy |
| 08/11/2023 | 879.05% | HC Wainwright & Co. | → $5 | Reiterates | Buy → Buy |
| 08/08/2023 | 1074.86% | Berenberg | → $6 | Assumes | → Buy |
| 06/05/2023 | 879.05% | HC Wainwright & Co. | $6 → $5 | Maintains | Buy |
| 05/24/2023 | 1074.86% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 03/27/2023 | 1270.67% | Wells Fargo | → $7 | Assumes | → Overweight |
| 03/24/2023 | 95.81% | Stifel | $2 → $1 | Maintains | Hold |
| 03/24/2023 | 1074.86% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 12/12/2022 | 1270.67% | Wells Fargo | $8 → $7 | Maintains | Overweight |
| 12/12/2022 | 1074.86% | Piper Sandler | $7 → $6 | Maintains | Overweight |
| 12/12/2022 | 1074.86% | SVB Leerink | $10 → $6 | Maintains | Outperform |
| 12/12/2022 | 1074.86% | HC Wainwright & Co. | → $6 | Initiates Coverage On | → Buy |
| 10/10/2022 | 291.62% | Stifel | $9 → $2 | Downgrades | Buy → Hold |
| 06/23/2022 | 1662.29% | SVB Leerink | $10 → $9 | Maintains | Outperform |
| 03/31/2022 | 1270.67% | Piper Sandler | → $7 | Initiates Coverage On | → Overweight |
| 02/23/2022 | 2249.72% | Cantor Fitzgerald | → $12 | Initiates Coverage On | → Overweight |
| 10/21/2021 | 1858.1% | Truist Securities | → $10 | Initiates Coverage On | → Buy |
| 10/12/2021 | 2249.72% | SVB Leerink | $13 → $12 | Maintains | Outperform |
| 09/30/2021 | 2249.72% | Stifel | → $12 | Initiates Coverage On | → Buy |
| 03/31/2021 | 2837.15% | Credit Suisse | → $15 | Initiates Coverage On | → Outperform |
| 03/24/2021 | 2837.15% | Wells Fargo | $10 → $15 | Maintains | Overweight |
| 03/11/2021 | 2641.34% | SVB Leerink | $9 → $14 | Maintains | Outperform |
| 11/11/2020 | 1662.29% | SVB Leerink | $8 → $9 | Maintains | Outperform |
| 06/24/2020 | 1466.48% | SVB Leerink | $7 → $8 | Maintains | Outperform |
| 03/28/2019 | 1466.48% | SVB Leerink | → $8 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 09/07/2023 | 1270.67% | 康託·菲茨傑拉德 | →$7 | 重申 | 超重→超重 |
| 2023年08月11日 | 1074.86% | Truist證券 | $8→$6 | 維護 | 買 |
| 2023年08月11日 | 879.05% | HC Wainwright公司 | →$5 | 重申 | 購買→購買 |
| 2023/08/08 | 1074.86% | 貝倫伯格 | →$6 | 假設 | →購買 |
| 06/05/2023 | 879.05% | HC Wainwright公司 | $6→$5 | 維護 | 買 |
| 2023年05月24日 | 1074.86% | HC Wainwright公司 | →$6 | 重申 | 購買→購買 |
| 03/27/2023 | 1270.67% | 富國銀行 | →$7 | 假設 | →超重 |
| 03/24/2023 | 95.81% | Stifel | $2→$1 | 維護 | 保持 |
| 03/24/2023 | 1074.86% | HC Wainwright公司 | →$6 | 重申 | →購買 |
| 2022年12月12日 | 1270.67% | 富國銀行 | $8→$7 | 維護 | 超重 |
| 2022年12月12日 | 1074.86% | 派珀·桑德勒 | $7→$6 | 維護 | 超重 |
| 2022年12月12日 | 1074.86% | SVB Leerink | $10→$6 | 維護 | 跑贏大盤 |
| 2022年12月12日 | 1074.86% | HC Wainwright公司 | →$6 | 開始承保 | →購買 |
| 2022年10月10日 | 291.62% | Stifel | $9→$2 | 評級下調 | 購買→Hold |
| 2022/06/23 | 1662.29% | SVB Leerink | $10→$9 | 維護 | 跑贏大盤 |
| 03/31/2022 | 1270.67% | 派珀·桑德勒 | →$7 | 開始承保 | →超重 |
| 02/23/2022 | 2249.72% | 康託·菲茨傑拉德 | →$12 | 開始承保 | →超重 |
| 2021/10/21 | 1858.1% | Truist證券 | →$10 | 開始承保 | →購買 |
| 10/12/2021 | 2249.72% | SVB Leerink | $13→$12 | 維護 | 跑贏大盤 |
| 09/30/2021 | 2249.72% | Stifel | →$12 | 開始承保 | →購買 |
| 03/31/2021 | 2837.15% | 瑞士信貸 | →$15 | 開始承保 | →跑贏大盤 |
| 03/24/2021 | 2837.15% | 富國銀行 | $10→$15 | 維護 | 超重 |
| 03/11/2021 | 2641.34% | SVB Leerink | $9→$14 | 維護 | 跑贏大盤 |
| 11/11/2020 | 1662.29% | SVB Leerink | $8→$9 | 維護 | 跑贏大盤 |
| 06/24/2020 | 1466.48% | SVB Leerink | $7→$8 | 維護 | 跑贏大盤 |
| 2019/03/28 | 1466.48% | SVB Leerink | →$8 | 開始承保 | →跑贏大盤 |
What is the target price for Affimed (AFMD)?
阿基米德(AFMD)的目標價是多少？
The latest price target for Affimed (NASDAQ: AFMD) was reported by Cantor Fitzgerald on September 7, 2023. The analyst firm set a price target for $7.00 expecting AFMD to rise to within 12 months (a possible 1270.67% upside). 14 analyst firms have reported ratings in the last year.
康託·菲茨傑拉德於2023年9月7日報道了Affimed(納斯達克代碼：AFMD)的最新目標價。這家分析公司將目標價定為7美元，預計AFMD將在12個月內上漲(可能上漲1270.67%)。過去一年，有14家分析公司公佈了評級。
What is the most recent analyst rating for Affimed (AFMD)?
AFMD的最新分析師評級是多少？
The latest analyst rating for Affimed (NASDAQ: AFMD) was provided by Cantor Fitzgerald, and Affimed reiterated their overweight rating.
阿基米德(納斯達克代碼：AFMD)的最新分析師評級由坎託·菲茨傑拉德提供，阿基米德重申其增持評級。
When is the next analyst rating going to be posted or updated for Affimed (AFMD)?
Affimed(AFMD)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Affimed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Affimed was filed on September 7, 2023 so you should expect the next rating to be made available sometime around September 7, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Affimed的高管和客戶交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Affimed的上一次評級是在2023年9月7日提交的，所以你應該預計下一次評級將在2024年9月7日左右提供。
Is the Analyst Rating Affimed (AFMD) correct?
分析師評級確認(AFMD)正確嗎？
While ratings are subjective and will change, the latest Affimed (AFMD) rating was a reiterated with a price target of $0.00 to $7.00. The current price Affimed (AFMD) is trading at is $0.51, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Affimed(AFMD)評級被重申，目標價在0.00美元至7.00美元之間。目前Affimed(AFMD)的交易價格為0.51美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。